The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States.
Hartnell
G G
GG
Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland, USA. gandjhartnell@erols.com
Gates
J
J
D002478:Cells, Cultured; D017277:Drug Approval; D004345:Drug Industry / Q000592:standards; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000600:supply & distribution; D006801:Humans; D007668:Kidney; D010960:Plasminogen Activators / Q000009:adverse effects / Q000138:chemical synthesis / Q000600:supply & distribution*; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000138:chemical synthesis / Q000600:supply & distribution*
D005343:Fibrinolytic Agents; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator